Thousands of Australians battling a debilitating form of multiple sclerosis have been granted a reprieve, as a groundbreaking ...

The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ...

Voyxact, an APRIL inhibitor, receives FDA accelerated approval for adults with primary IgA nephropathy to reduce proteinuria.

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

Drs Kathy Miller and Alexandra Thomas discuss important toxicities for breast cancer HER2-targeted therapies and how to improve the patient experience.

If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.

Chargers, Eagles in giving mood with three-turnover play Paramount makes $77.9 billion hostile bid for Warner after Netflix ...

Collagen is one of the most common proteins that exists in our bodies. It provides a framework for almost everything, ...